Skip to main content

The Patient Journey in Prostate Cancer: Key Points for Nurses

  • Chapter
  • First Online:
Principle of Nursing in Oncology

Part of the book series: Principles of Specialty Nursing ((PSN))

  • 1370 Accesses

Abstract

The optimal care pathway for patients with prostate cancer (PCa) should be multidisciplinary and multi-professional. Nurses from a variety of disciplines (e.g. medical oncology, urology, radiation oncology) should be implicated in educating patients and guiding patient care across the broad spectrum of available treatments.

For this purpose, nurses involved in managing PCa patients should be educated about the different treatments and their possible adverse events. Most PCa are slow-growing indolent tumours that will be best managed by active surveillance. Nurses play an important role in reassuring and empowering the patient in that process. Localised disease is best treated by surgery and/or radiotherapy, each offering a different philosophical approach. Nurses play a central role in guiding the patient in the difficult decision of the treatment choice. They will be the guardian of a shared decision-making and protect the principle of equipoise by involving patients in the treatment choices. Advanced PCa, at its various stages of progression, is most often treated by hormonal therapy. Hormone therapy does not eradicate PCa but rather switches it to a more chronic state. This means that the patients will be treated for an extended period of time. Hormone therapy may profoundly affect various emotional and physical aspects of the patients and severely impacts its well-being. Countermeasures are known but rarely explained to patients. Nurses are ideally positioned to provide treatment information, education and self-management recommendations regarding side effects and symptom management. According to these numerous treatments, all nurses will be there to provide emotional and psychological support regarding patient’s coping process which will improve adherence in his treatment plan.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 69.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Global Burden of Disease Cancer C, Fitzmaurice C, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524–48.

    Article  Google Scholar 

  2. Cuzick J, Thorat MA, Andriole G, et al. Prevention and early detection of prostate cancer. Lancet Oncol. 2014;15(11):e484–92.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Butoescu V, Ambroise J, Stainier A, Dekairelle AF, Gala JL, Tombal B. Does genotyping of risk-associated single nucleotide polymorphisms improve patient selection for prostate biopsy when combined with a prostate cancer risk calculator? Prostate. 2014;74(4):365–71.

    Article  CAS  PubMed  Google Scholar 

  4. Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol. 2015;67(5):825–36.

    Google Scholar 

  5. Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol. 2018;73(4):560–9.

    Article  PubMed  Google Scholar 

  6. Sartor O, Eisenberger M, Kattan MW, Tombal B, Lecouvet F. Unmet needs in the prediction and detection of metastases in prostate cancer. Oncologist. 2013;18(5):549–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Epstein JI, Amin MB, Reuter VE, Humphrey PA. Contemporary Gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2017;41(4):e1–7.

    Article  PubMed  Google Scholar 

  8. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–29.

    Article  PubMed  Google Scholar 

  9. Droz JP, Aapro M, Balducci L, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 2014;15(9):e404–14.

    Article  PubMed  Google Scholar 

  10. Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol. 2011;29(10):1335–41.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the cumulative illness rating scale in a geriatric residential population. J Am Geriatr Soc. 1995;43(2):130–7.

    Article  CAS  PubMed  Google Scholar 

  12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.

    Article  CAS  PubMed  Google Scholar 

  13. Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate Cancer. N Engl J Med. 2016;375(15):1415–24.

    Article  PubMed  Google Scholar 

  14. Wilt TJ, Jones KM, Barry MJ, et al. Follow-up of prostatectomy versus observation for early prostate Cancer. N Engl J Med. 2017;377(2):132–42.

    Article  PubMed  Google Scholar 

  15. Ahmed HU, Bosaily AE, Brown LC, et al. The PROMIS study: a paired-cohort, blinded confirmatory study evaluating the accuracy of multi-parametric MRI and TRUS biopsy in men with an elevated PSA. J Clin Oncol. 2016;34(suppl):a5000.

    Article  Google Scholar 

  16. Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Barocas DA, Alvarez J, Resnick MJ, et al. Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years. JAMA. 2017;317(11):1126–40.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5):446–53.

    Article  CAS  PubMed  Google Scholar 

  19. Tyson MD 2nd, Koyama T, Lee D, et al. Effect of prostate cancer severity on functional outcomes after localized treatment: comparative effectiveness analysis of surgery and radiation study results. Eur Urol. 2018;74(1):26–33.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Vale CL, Fisher DJ, White IR, et al. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Ann Oncol. 2018;29(5):1249–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR. Gonadotropin-releasing hormone receptors. Endocr Rev. 2004;25(2):235–75.

    Article  CAS  PubMed  Google Scholar 

  22. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531–8.

    Article  CAS  PubMed  Google Scholar 

  23. Klotz L, Miller K, Crawford ED, et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol. 2014;66(6):1101–8.

    Article  CAS  PubMed  Google Scholar 

  24. Bourke L, Smith D, Steed L, et al. Exercise for men with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69(4):693–703.

    Article  PubMed  Google Scholar 

  25. Lebret T, Coloby P, Descotes JL, Droupy S, Geraud M, Tombal B. Educational tool-kit on diet and exercise: survey of prostate cancer patients about to receive androgen deprivation therapy. Urology. 2010;76(6):1434–9.

    Article  PubMed  Google Scholar 

  26. Tombal B. A holistic approach to androgen deprivation therapy: treating the cancer without hurting the patient. Urol Int. 2009;83(4):373–8.

    Article  PubMed  Google Scholar 

  27. Aucoin MW, Wassersug RJ. The sexuality and social performance of androgen-deprived (castrated) men throughout history: implications for modern day cancer patients. Soc Sci Med. 2006;63(12):3162–73.

    Article  PubMed  Google Scholar 

  28. Moyad MA. Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients. Urol Oncol. 2005;23(1):56–64.

    Article  PubMed  Google Scholar 

  29. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol. 1997;79(6):933–41.

    Article  CAS  PubMed  Google Scholar 

  30. Pezaro C, Mukherji D, Tunariu N, et al. Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. Br J Cancer. 2013;109(2):325–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D’Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009;302(8):866–73.

    Article  CAS  PubMed  Google Scholar 

  32. Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65(3):565–73.

    Article  CAS  PubMed  Google Scholar 

  33. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91(4):1305–8.

    Article  CAS  PubMed  Google Scholar 

  34. Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102(1):39–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Galvao DA, Nosaka K, Taaffe DR, et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc. 2006;38(12):2045–52.

    Article  PubMed  Google Scholar 

  36. Eriksson S, Eriksson A, Stege R, Carlstrom K. Bone mineral density in patients with prostate cancer treated with orchiectomy and with estrogens. Calcif Tissue Int. 1995;57(2):97–9.

    Article  CAS  PubMed  Google Scholar 

  37. Alibhai SM, Duong-Hua M, Cheung AM, et al. Fracture types and risk factors in men with prostate Cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol. 2010;184(3):918–23.

    Article  PubMed  Google Scholar 

  38. Nguyen PL, Alibhai SM, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825–36.

    Article  CAS  PubMed  Google Scholar 

  39. Benton MJ, White A. Osteoporosis: recommendations for resistance exercise and supplementation with calcium and vitamin D to promote bone health. J Community Health Nurs. 2006;23(4):201–11.

    Article  PubMed  Google Scholar 

  40. Network NCC. Prostate cancer. 2017. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed 21 Feb 2017, 2015.

  41. Butoescu V, Tombal B. Practical guide to bone health in the spectrum of advanced prostate cancer. Can J Urol. 2014;21(2 Suppl 1):84–92.

    PubMed  Google Scholar 

  42. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26(28):4563–71.

    Article  CAS  PubMed  Google Scholar 

  43. Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60.

    Article  CAS  PubMed  Google Scholar 

  44. James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–60.

    Article  CAS  PubMed  Google Scholar 

  46. Agency EM. Summary of the European public assessment report (EPAR) for Zytiga. 2018. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002321/WC500112861.pdf. Accessed 30 Apr 2018.

  47. Tombal B. Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient? Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2012;23(Suppl 10):x251–8.

    Article  Google Scholar 

  48. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;375(9724):1437–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.

    Article  CAS  PubMed  Google Scholar 

  51. Chowdhury S, Shore N, Saad F, et al. Fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide: data from randomised clinical trials. Ann Oncol. 2016;27 (suppl_6):739P.

    Google Scholar 

  52. Agency EM. Summary of the European public assessment report (EPAR) for Xtandi. 2015. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002639/human_med_001663.jsp&mid=WC0b01ac058001d124. Accessed 30 Apr 2018, 2017.

  53. Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6):555–67.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Christine Remacle .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Remacle, C. (2019). The Patient Journey in Prostate Cancer: Key Points for Nurses. In: Charnay-Sonnek, F., Murphy, A. (eds) Principle of Nursing in Oncology . Principles of Specialty Nursing. Springer, Cham. https://doi.org/10.1007/978-3-319-76457-3_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-76457-3_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-76456-6

  • Online ISBN: 978-3-319-76457-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics